[MAXIS] QoQ Quarter Result on 31-Mar-2012 [#1]

Stock
[MAXIS] MAXIS BERHAD
Announcement Date
31-May-2012
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2012
Quarter
31-Mar-2012 [#1]
Profit Trend
QoQ- -36.44%
YoY- 6.12%
Quarter Report
Latest QR
Upcoming QR
MAXIS's Result
MAXIS's Financial Summary
View:
Show?
Quarter Result
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
Revenue 2,306,000 2,216,000 2,216,000 2,229,000 2,265,000 2,244,000 2,158,000 4.50%
PBT 547,000 632,000 630,000 767,000 760,000 746,000 757,000 -19.39%
Tax -169,000 -189,000 -164,000 -194,000 141,000 -208,000 -205,000 -12.02%
NP 378,000 443,000 466,000 573,000 901,000 538,000 552,000 -22.22%
-
NP to SH 378,000 442,000 464,000 572,000 900,000 537,000 551,000 -22.12%
-
Tax Rate 30.90% 29.91% 26.03% 25.29% -18.55% 27.88% 27.08% -
Total Cost 1,928,000 1,773,000 1,750,000 1,656,000 1,364,000 1,706,000 1,606,000 12.89%
-
Net Worth 7,106,399 7,266,779 7,334,193 8,128,421 8,100,000 7,682,083 8,076,301 -8.14%
Dividend
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
Div 1,209,600 599,322 598,709 602,105 1,200,000 596,666 603,835 58.57%
Div Payout % 320.00% 135.59% 129.03% 105.26% 133.33% 111.11% 109.59% -
Equity
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
Net Worth 7,106,399 7,266,779 7,334,193 8,128,421 8,100,000 7,682,083 8,076,301 -8.14%
NOSH 7,560,000 7,491,525 7,483,871 7,526,315 7,500,000 7,458,333 7,547,945 0.10%
Ratio Analysis
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
NP Margin 16.39% 19.99% 21.03% 25.71% 39.78% 23.98% 25.58% -
ROE 5.32% 6.08% 6.33% 7.04% 11.11% 6.99% 6.82% -
Per Share
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
RPS 30.50 29.58 29.61 29.62 30.20 30.09 28.59 4.38%
EPS 5.00 5.90 6.20 7.60 12.00 7.20 7.30 -22.20%
DPS 16.00 8.00 8.00 8.00 16.00 8.00 8.00 58.40%
NAPS 0.94 0.97 0.98 1.08 1.08 1.03 1.07 -8.23%
Adjusted Per Share Value based on latest NOSH - 7,526,315
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
RPS 29.44 28.29 28.29 28.46 28.92 28.65 27.55 4.50%
EPS 4.83 5.64 5.92 7.30 11.49 6.86 7.03 -22.04%
DPS 15.44 7.65 7.64 7.69 15.32 7.62 7.71 58.54%
NAPS 0.9072 0.9277 0.9363 1.0377 1.0341 0.9807 1.031 -8.13%
Price Multiplier on Financial Quarter End Date
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
Date 31/12/12 28/09/12 29/06/12 30/03/12 30/12/11 30/09/11 30/06/11 -
Price 6.65 6.92 6.39 6.09 5.48 5.32 5.48 -
P/RPS 21.80 23.39 21.58 20.56 18.15 17.68 19.17 8.90%
P/EPS 133.00 117.29 103.06 80.13 45.67 73.89 75.07 46.16%
EY 0.75 0.85 0.97 1.25 2.19 1.35 1.33 -31.62%
DY 2.41 1.16 1.25 1.31 2.92 1.50 1.46 39.46%
P/NAPS 7.07 7.13 6.52 5.64 5.07 5.17 5.12 23.88%
Price Multiplier on Announcement Date
31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 30/06/11 CAGR
Date 26/02/13 28/11/12 30/08/12 31/05/12 24/02/12 30/11/11 25/08/11 -
Price 6.35 6.50 7.04 6.19 5.99 5.50 5.42 -
P/RPS 20.82 21.97 23.78 20.90 19.83 18.28 18.96 6.40%
P/EPS 127.00 110.17 113.55 81.45 49.92 76.39 74.25 42.79%
EY 0.79 0.91 0.88 1.23 2.00 1.31 1.35 -29.92%
DY 2.52 1.23 1.14 1.29 2.67 1.45 1.48 42.36%
P/NAPS 6.76 6.70 7.18 5.73 5.55 5.34 5.07 21.03%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment